Nymox Pharmaceutical Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial

Published: Jul 12, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HASBROUCK HEIGHTS, N.J., July 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee review of ongoing safety data for the Company's NX02-0017 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The July 9, 2013 Safety Monitoring Committee meeting found no significant safety concerns to date. The Company's pivotal Phase 3 trials have completed enrollment and treatment (a single intraprostatic injection of either drug or placebo) and patient evaluation is continuing at over 70 well-known urology investigative sites across the U.S.

Help employers find you! Check out all the jobs and post your resume.

Back to news